title: Are we ready for the 10% solution?
authors.affiliation: Cancer Therapy Evaluation Program, Biometric Research Branch, and Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: Helen X
authors.initials: HX
authors.lastname: Chen
authors.forename: Larry V
authors.initials: LV
authors.lastname: Rubinstein
authors.forename: Lalitha K
authors.initials: LK
authors.lastname: Shankar
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Abrams
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
references.citation: Eur Urol. 2011 Dec;60(6):1273-9
references.pmid: 21784574
references.citation: Ann Oncol. 2010 May;21(5):936-41
references.pmid: 19889607
references.citation: Oncologist. 2014 May;19(5):507-14
references.pmid: 24755461
references.citation: Discov Med. 2010 Nov;10(54):394-405
references.pmid: 21122471
references.citation: Eur J Cancer. 2012 Jul;48(10):1512-8
references.pmid: 22342553
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: AJR Am J Roentgenol. 2010 Jan;194(1):157-65
references.pmid: 20028918
references.citation: Eur Urol. 2011 May;59(5):856-62
references.pmid: 21306819